| Literature DB >> 36268372 |
Anushree Rai1,2, Olivier Uwishema1,3,4, Lama Uweis1,5, Rayyan El Saleh1,5, Sara Arab1,5, Mortada Abbass1,5, Jack Wellington1,6, Felix Musabirema7, Irem Adanur1,4, Chinyere Vivian Patrick Onyeaka8.
Abstract
On July 21, 2022, the USA witnessed the first case of poliomyelitis after 3 decades of its eradication. Poliomyelitis is a crippling disease that results from infection with any one of the three related poliovirus types (referred to as types P1, P2, and P3), members of the enterovirus (picornavirus) family. The New York State Department of Health confirmed that a case of paralytic poliomyelitis was reported from a 20-year-old Hungarian traveller residing in Rockland County. The detected viral sequence has been found to have vaccine-derived poliovirus type 2 (VDPV2) suggesting an origin from the live attenuated oral polio vaccine (OPV). Since immunisation remains the only preventable measure, this article explores suggestions from the Centers for Disease Control and Prevention on reliable Inactivated (killed) polio vaccination in high-risk patients along with early case detection and treatment. In light of the above-mentioned findings, this research further details future recommendations like cessation of the OPV, encouragement of inactivated polio vaccine (IPV) in vaccination schedules, sensitive epidemiological surveillance system and appropriate training for healthcare providers. The affected countries have been further advised to have effective outbreak response strategy plans in place so that they can respond and stay prepared for such outbreaks in the future.Entities:
Keywords: OPV; Polio; USA; United States of America; VAPP; VDPV2
Year: 2022 PMID: 36268372 PMCID: PMC9577438 DOI: 10.1016/j.amsu.2022.104563
Source DB: PubMed Journal: Ann Med Surg (Lond) ISSN: 2049-0801